Secondary somatic glioblastoma arising from a mature ovarian cystic teratoma in a patient with underlying Li-Fraumeni syndrome

Parker L Bussies; Danielle B Chau; Jonathan T Hunt; Maria Luisa C Policarpio-Nicolas; Cameron Friedman; Jesse K McKenney; Gabrielle A Yeaney; David M Peereboom; Lindsey Beffa

doi:10.1016/j.gore.2023.101279

Secondary somatic glioblastoma arising from a mature ovarian cystic teratoma in a patient with underlying Li-Fraumeni syndrome

Gynecol Oncol Rep. 2023 Sep 26:49:101279. doi: 10.1016/j.gore.2023.101279. eCollection 2023 Oct.

Authors

Parker L Bussies¹, Danielle B Chau¹, Jonathan T Hunt¹, Maria Luisa C Policarpio-Nicolas², Cameron Friedman³, Jesse K McKenney³, Gabrielle A Yeaney², David M Peereboom⁴, Lindsey Beffa¹

Affiliations

¹ Women's Health Institute, Cleveland Clinic Foundation, Cleveland, OH, United States.
² Department of Pathology, Cleveland Clinic Foundation, Cleveland, OH, United States.
³ Genomic Medicine Institute, Cleveland Clinic Foundation, Cleveland, OH, United States.
⁴ Brain Tumor and Neuro-Oncology Center, Cleveland Clinic Foundation, Cleveland, OH, United States.

Abstract

•First report of a secondary somatic glioblastoma arising from MCT-MT in a patient with underlying Li-Fraumeni syndrome.•The rarity of glioblastoma arising from MCT-MT warrants investigation for underlying genetic predisposition.•Glioblastomas arising from MCT-MT appear to exhibit wild type IDH gene status.•Advanced-stage glioblastoma arising from MCT-MT exhibits aggressive behavior and requires adjuvant therapy.•Optimal adjuvant therapy regimen for glioblastoma arising from MCT-MT remains unknown.

Keywords: Advanced-stage treatment; IDH; Li-Fraumeni Syndrome; Mature ovarian cystic teratoma; Secondary somatic glioblastoma; TP53.

Publication types

Case Reports